EmendoBio - Ownership and Business Overview

Life ScienceCompany

EmendoBio Ownership

Who owns EmendoBio?

EmendoBio is owned by AnGes. It was acquired on December 15, 2020.

EmendoBio Business Overview

Where is EmendoBio headquartered?

EmendoBio is headquartered in New York, New York.

What sector is EmendoBio in?

EmendoBio is a life science company.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.

EmendoBio, Inc.

400 W 61st Street,
New York, New York 10069
United States,
(917) 675-5585
www.emendobio.com

EmendoBio, Inc. is a CRISPR gene-editing company leveraging dual proprietary technology platforms to enable high precision gene-editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome while its target‐specific optimization platform enables highly precise editing, including allele-specific editing while maintaining high efficiencies. EmendoBio is based in New York City.


 Subscribe to unlock this and 208,718
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.